Evidence map›Paper›PMID 28356971›Full record

ArticleOncology letters2017

Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients.

Yanwei Luo, Xinye Wang, Weihong Niu, Heran Wang, Qiuyuan Wen, Songqing Fan, Ran Zhao, Zheng Li, Wei Xiong, Shuping Peng and 5 more

Expression of concernAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. The Emerging Roles of miR-125b in Cancers.Cancer management and research · 2020
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Yanwei LuoCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China; Department of Transfusion, The Third Xiang-Ya Hospital, Central South University, Changsha, Hunan 410013, P.R. China.
Xinye WangCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China.
Weihong NiuCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China.
Heran WangCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China.
Qiuyuan WenDepartment of Pathology, The Second Xiang-Ya Hospital, Central South University, Changsha, Hunan 410011, P.R. China.
Songqing FanDepartment of Pathology, The Second Xiang-Ya Hospital, Central South University, Changsha, Hunan 410011, P.R. China.
Ran ZhaoCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China.
Zheng LiCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China.
Wei XiongCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China.
Shuping PengCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China.
Zhaoyang ZengCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China.
Xiaoling LiCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China.
Guiyuan LiCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China.
Ming TanMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Ming ZhouCancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China; Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan 410078, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer, the second most common cancer worldwide, is the leading cause of cancer-associated mortality in women, accounting for ~15% of all cancer-associated mortalities in women. The development, local invasion and metastasis of breast cancer are associated with the dysregulation and mutation of numerous genes and epigenetic mechanisms, including coding RNA and non-coding RNA, such as microRNAs (miRs/miRNAs). Previous studies have shown a dual-faced role of miR-125b in breast cancer. In the present study, a total of 221 paraffin-embedded breast cancer and 49 paraffin-embedded non-cancerous breast tissue samples were collected.

Indexed as

breast cancerHER2miR-125bpaclitaxelprognosis

Identifiers

PMID28356971
PMCPMC5351301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.